Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "AREA[SponsorSearch](Lumos Pharma)"
Count: 38
Selected: 0
| NCT ID | Title |
|---|
| NCT05250063 | Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial | ||
| NCT04806854 | PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency. | ||
| NCT04614337 | Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial) | ||
| NCT05469490 | Safety of Navoximod and NLG802 With Stereotactic Body Radiotherapy (SBRT) Treatment of Advanced Solid Tumors | ||
| NCT03852446 | Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male Volunteers | ||
| NCT03372239 | Oral Bioavailability,and Food Effect Study and Single Ascending Dose PK Study in Healthy Male Volunteers | ||
| NCT03301636 | A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma | ||
| NCT03165188 | Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy | ||
| NCT03164603 | NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors | ||
| NCT02835729 | A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia | ||
| NCT02648711 | Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors | ||
| NCT02502708 | Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors | ||
| NCT02460367 | Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer | ||
| NCT02405585 | Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer | ||
| NCT02389985 | A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | ||
| NCT02380677 | Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors | ||
| NCT02187302 | CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC) | ||
| NCT02077881 | Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer | ||
| NCT02073123 | Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma | ||
| NCT02054520 | Immunotherapy Study for Patients With Stage IV Melanoma | ||
| NCT02052648 | Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors | ||
| NCT02035358 | Immunotherapy Study for Metastatic Renal Cell Cancer | ||
| NCT01836432 | Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer | ||
| NCT01792050 | Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer | ||
| NCT01774578 | Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer | ||
| NCT01380769 | A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer | ||
| NCT01072981 | Immunotherapy Study for Surgically Resected Pancreatic Cancer | ||
| NCT00753740 | Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients. | ||
| NCT00739609 | IDO Inhibitor Study for Relapsed or Refractory Solid Tumors | ||
| NCT00614601 | Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer | ||
| NCT00569387 | Vaccine Study for Surgically Resected Pancreatic Cancer | ||
| NCT00420732 | Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer | ||
| NCT00333502 | Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors | ||
| NCT00300612 | Vaccine Treatment for Advanced Malignant Melanoma | ||
| NCT00255827 | Vaccine Treatment for Surgically Resected Pancreatic Cancer | ||
| NCT00105053 | Vaccine Treatment for Hormone Refractory Prostate Cancer | ||
| NCT00090480 | Vaccine Treatment for Advanced Breast Cancer | ||
| NCT00073398 | Vaccine Treatment for Advanced Non-Small Cell Lung Cancer |
